Market Insight: Bright Future Ahead for Biopharmaceutical Contract Manufacturing, Frost & Sullivan

London, United Kingdom, October 03, 2013 --(PR.com)-- Considerable growth opportunities lie ahead for biopharmaceutical contract manufacturing organisations (CMOs). With blockbuster biologics worth over $100 billion due to lose patent protection by 2019, the global biosimilars market is projected to grow at a robust compound annual growth rate (CAGR) of 60.4 percent between 2012 and 2019.

A new market insight from Frost & Sullivan, Biopharmaceutical Contract Manufacturing, finds advances in bioprocessing technologies, as well as innovation in biopharmaceuticals production with transgenic plants and animals, stem cells and cloning, are likely to have a direct impact on the market.

“Due to the steep cost and long time needed to build, equip and validate a biomanufacturing facility, the majority of biopharmaceutical companies prefer leveraging the expertise of CMOs,” notes Frost & Sullivan Healthcare Senior Research Analyst Aiswariya Chidambaram. “CMOs have made substantial investments in infrastructure, technology, and personnel in recent years, and are capable of providing uncomplicated, timely, and cost-effective services. They are also well versed with regulatory compliances and work closely with regulatory agencies, thereby reducing time-to-market.”

Disposable technology is a key biomanufacturing trend and presents attractive opportunities for minimising production costs, owing to its customizable design, enhanced productivity, and significant operational benefits. Disposable equipment and single use bioreactors are considered a viable alternative to conventional stainless steel equipment, due to their flexibility, short start-up time, quick changeover between production campaigns, and absence of Clean in Place, Steam in Place, and large volumes of Water for Injection. Single use technologies are specially designed for multi-product contract manufacturing with additional benefits, such as simple transfer of operations between sites and their ability of being easily expandable for larger volumes.

Advances in upstream and downstream processing technologies will also impact the industry. With 20 percent of biotech manufacturing costs accounting for upstream processing activities, and 40 percent for downstream ones, most companies and CMOs are gearing up to adopt new technologies to optimise efficiency. In 2011 the global industry witnessed a 6.2 percent budget increase for integrating new technologies in upstream processing. Reduction of quality variability in the product - impurities such as aggregates, glycosylation variants, and so forth - and cell viability will be the key focus areas of upstream processing in biomanufacturing. Downstream processing technologies follow two different trends specific to mAbs and recombinant proteins, specifically in the purification processes. In the next five years, exploration of alternative purification methods will be crucial for CMOs.

Advances in lyophilisation and increasing applications of process analytical technology (PAT) will also attract attention. Innovations such as automated loading processes into the dryer in place of manual loading contribute to minimising human error and maximising productivity. Also, manufacturers increasingly prefer the implementation of PAT and standardisation of their processes, rather than relying on the validation of finished products. Near infrared spectroscopy (NIR) is one of the latest technologies which provides potential real-time control of cells in fermentation, specifically in mammalian cell culture processes. The significant enhancement of purity levels and product efficiency are expected to drive the demand for this novel technology throughout the forecast period.

Mammalian cell-based contract manufacturing is expected to sustain the industry’s future expansion. This segment currently constitutes nearly two thirds of the sales revenue of the global biopharmaceutical contract manufacturing market and is anticipated to grow as high as 65 percent over the next five years, at a significantly higher rate than microbial cell-based contract manufacturing segment.

Increasing adoption of the Large Molecules model by big pharma companies will also boost prospects. Of the top 15 pharmaceutical companies, nearly 80 percent are expected to experience a net growth in their biologics portfolio. The big pharma shift to large molecules will likely be led by monoclonal antibodies (mAbs) and is projected to grow at a CAGR of 10.8 percent from 2012 to 2017.

Companies will also increasingly outsource crucial operations and will seek to adopt an integrated/risk-sharing business model. The aim is to provide a “one-stop-shop” option for the biopharmaceutical companies where they can exploit the resources and expertise of the CMOs to reap maximum benefits, while they concentrate on their core capabilities and R&D activities.

If you are interested in more information on this Market Insight, please send an email to Anna Zanchi, Corporate Communications, at anna.zanchi@frost.com